Your browser doesn't support javascript.
loading
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu, Khoan; Wu, Chi-Heng; Yang, Chen-Yen; Zhan, Aaron; Cavallone, Erika; Berry, Wade; Heeter, Pamela; Pincus, Laura; Wieduwilt, Matthew J; William, Basem M; Andreadis, Charalambos; Kaplan, Lawrence K; McCormick, Frank; Porcu, Pierluigi; Brammer, Jonathan E; Ai, Weiyun Z.
Afiliação
  • Vu K; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Wu CH; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Yang CY; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Zhan A; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Cavallone E; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Berry W; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Heeter P; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
  • Pincus L; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Wieduwilt MJ; Moores Cancer Center, University of California, San Diego, California.
  • William BM; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
  • Andreadis C; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • Kaplan LK; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California.
  • McCormick F; Hellen Diller Family Cancer Center, University of California, San Francisco, California.
  • Porcu P; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
  • Brammer JE; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
  • Ai WZ; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California. weiyun.ai@ucsf.edu.
Clin Cancer Res ; 26(5): 1000-1008, 2020 03 01.
Article em En | MEDLINE | ID: mdl-31772119
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células T / Linfoma Cutâneo de Células T / Linfoma de Células T Periférico / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células T / Linfoma Cutâneo de Células T / Linfoma de Células T Periférico / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article